Sublimity To Present at Cowen and Company 39th Annual Health Care Conference

Boston, MA., March 07, 2019 – Sublimity Therapeutics, a specialty pharmaceutical company focused on the treatment of ulcerative colitis, today announced that Albert Agro, Ph.D., Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, at 8:30 a.m. EDT at the Boston Marriott Copley Place, Boston.

The company recently launched a Phase 2b clinical trial, CYC-202. This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the safety, efficacy and tolerability of the company’s lead drug candidate, ST-0529, for patients with moderate to severe ulcerative colitis. Sublimity has initiated screening and enrollment of approximately 280 patients in 18 countries across Europe, Israel, Canada and the U.S.

Cowen hosts 10 to 15 major industry-specific conferences annually attracting top institutional investors and leading companies in multiple sectors including health care, technology, media & telecom, consumer, energy, aerospace and defense, industrials and transportation.

About Sublimity Therapeutics

Sublimity Therapeutics, a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California, is a clinical-stage biotechnology company dedicated to identifying and creating meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules and peptides that have the potential to make important contributions to human health.

About Ulcerative Colitis

It is estimated that ulcerative colitis affects approximately 1.7 million patients in North America, Europe and other developed countries. The moderate to severe patient segment represents the fastest growing market segment, with double-digit annual growth. The mainstays of treatment for this disease are anti-TNFs; however, these drugs are limited by their toxicities and safety liabilities. A large portion of patients are either unresponsive to initial front-line anti-TNF therapy or become refractory to treatment within the first year. Despite the introduction of new medicines, these patients still have significant unmet medical needs.

About Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH is one of the leading companies worldwide in gastroenterology with its products being sold in more than 60 countries. Its pharmaceuticals are used successfully to treat inflammatory bowel disease, cholestatic liver disease, irritable bowel syndrome, constipation, and for colon cleansing prior to colonoscopies. The Falk Foundation, which is associated with the company, provides medical information via international symposia, forums, postgraduate courses and literature services. Over the past 45 years the Falk Foundation has sponsored more than 200 international Falk symposia and workshops in which over 100,000 researchers and physicians from 110 countries have come together to advance knowledge in gastroenterology and hepatology.

Forward-Looking Statements

This press release contains forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast,” “goal,” “objective,” “aim” and other words and terms of similar meaning or by using future dates in connection with any discussion thereof. In particular, statements, express or implied, concerning future actions, conditions or events, future operating results, including, but not limited to, the potential medical benefits of ST-0529, the perceived potential opportunity in the ulcerative colitis market for an oral alternative, the intended launch of the Phase 2b clinical trial and the success of such clinical trial and the launch and success of any future clinical trials, the ability to obtain required regulatory approval for ST-0529, and risks related Sublimity meeting some or all of the milestones required to be met for future funding by investors, are forward-looking statements. We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, and you are cautioned not to put undue reliance on forward-looking statements. Sublimity undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

Company Contact:
Albert Agro
President & CEO
Sublimity Therapeutics
info@sublimitytherapeutics.com

Media:
David Schull
Russo Partners LLC
David.Schull@RussoPartnersLLC.com
(212) 845-4271